Target validation: Linking target and chemical properties to desired product profile

Current Topics in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 1275-1283

  Wyatt, Paul G ^a   Gilbert, Ian H ^a   Read, Kevin D ^a   Fairlamb, Alan H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chemical validation; Drug resistance; Druggability; Genetic validation; Molecular targets; Neglected diseases; Target assessment; Target product profile

Indexed keywords

FK 506 BINDING PROTEIN; LIGAND; PHARMACOLOGICAL BIOMARKER;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CHEMICAL ANALYSIS; DRUG ACTIVATION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DEVELOPMENT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOXICITY; DRUG TRANSPORT; DRUG UPTAKE; EXPRESSION VECTOR; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC MANIPULATION; GENETIC TRAIT; GENETIC TRANSFECTION; HEALTH CARE NEED; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN GENOME; LEISHMANIA; MEDICAL INFORMATION; PATIENT IDENTIFICATION; PHYSIOLOGY; POINT MUTATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; RNA INTERFERENCE; SCORING SYSTEM; TARGET PRODUCT PROFILE; TOXOPLASMA GONDII; TRYPANOSOMA; VALIDATION PROCESS;

DRUG DESIGN; DRUG DISCOVERY; HUMANS; NEGLECTED DISEASES;

EID: 79960021792     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795429185     Document Type: Article

References (71)

1. Savioli, L.; Engels, D.; Daumerie, D.; Jannin, J.; Alvar, J.; Asiedu, K.; Gastellu-Etchegorry, M.; Simarro, P.; Mariotti, S. P. Response from Savioli and colleagues from the department of neglected tropical diseases, world health organization. Plos Med., 2006, 3, 936-938.
2. Trouiller, P.; Olliaro, P.; Torreele, E.; Orbinski, J.; Laing, R.; Ford, N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet, 2002, 359, 2188-2194.
3. Nwaka, S.; Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug. Discov., 2006, 5, 941-955.
4. Renslo, A. R.; McKerrow, J. H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol., 2006, 2, 701-710.
5. Brown, D.; Superti-Furga, G. Rediscovering the sweet spot in drug discovery. Drug Discov. Today, 2003, 8, 1067-1077.
6. Mackey, Z. B.; Baca, A. M.; Mallari, J. P.; Apsel, B.; Shelat, A.; Hansell, E. J.; Chiang, P. K.; Wolff, B.; Guy, K. R.; Williams, J.; McKerrow, J. H. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem. Biol. Drug Des., 2006, 67, 355-363.
7. Weisman, J. L.; Liou, A. P.; Shelat, A. A.; Cohen, F. E.; Guy, R. K.; DeRisi, J. L. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des., 2006, 67, 409-416.
8. O'Connor, K. A.; Roth, B. L. Finding new tricks for old drugs: An efficient route for public-sector drug discovery. Nat. Rev. Drug. Discov., 2005, 4, 1005-1014.
9. Baniecki, M. L.; Wirth, D. F.; Clardy, J. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob. Agents Chemother., 2007, 51, 716-723.
10. Tebbey, P. W.; Rink, C. Target product profile: A renaissance for its definition and use. J. Med. Market, 2009, 9, 301-307.
11. Frearson, J. A.; Wyatt, P. A.; Gilbert, I. H.; Fairlamb, A. H. Target assessment for antiparasitic drug discovery. Trends Parasitol., 2007, 23, 589-595.
12. Brun, R.; Blum, J.; Chappuis, F.; Burri, C. Human African trypanosomiasis. Lancet, 2010, 375, 148-159.
13. Croft, S. L.; Sundar, S.; Fairlamb, A. H. Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev., 2006, 19, 111-126.
14. Sullivan, D. J. Theories on malarial pigment formation and quinoline action. Int. J. Parasitol., 2002, 32, 1645-1653.
15. Rosenthal, P. J.; Meshnick, S. R. Hemoglobin catabolism and iron utilization by malaria parasites. Mol. Biochem. Parasitol., 1996, 83, 131-139.
16. Stuart, K. D.; Brun, R.; Croft, S. L.; Fairlamb, A. H.; Gurtler, R. E.; McKerrow, J. H.; Reed, S.; Tarleton, R. L. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest., 2008, 118, 1301-1310.
17. Ghannoum, M. A.; Rice, L. B. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev., 1999, 12, 501-517.
18. Docampo, R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interact., 1990, 73, 1-27.
19. Kubata, B. K.; Kabututu, Z.; Nozaki, T.; Munday, C. J.; Fukuzumi, S.; Ohkubo, K.; Lazarus, M.; Maruyama, T.; Martin, S. K.; Duszenko, M.; Urade, Y. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J. Exp. Med., 2002, 196, 1241-1251.
20. Docampo, R.; Stoppani, A. O. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi. Arch. Biochem. Biophys., 1979, 197, 317-321.
21. Wilkinson, S. R.; Taylor, M. C.; Horn, D.; Kelly, J. M.; Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. USA, 2008, 105, 5022-5027.
22. Nelson, D. J.; Bugge, C. J. L.; Elion, G. B.; Berens, R. L.; Marr, J. J. Metabolism of pyrazolo(3,4-d)pyrimidines in Leishmania braziliensis and Leishmania donovani. Allopurinol, oxipurinol, and 4-aminopyrazolo(3,4-d)pyrimidine. J. Biol. Chem., 1979, 254, 3959-3964.
23. Albert, A. Selective Toxicity; 5 ed.; Chapman and Hall: London, 1973.
24. Carter, N. S.; Fairlamb, A. H. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature, 1993, 361, 173-176.
25. Barrett, M. P.; Gilbert, I. H. Targeting of toxic compounds to the trypanosome's interior. Adv. Parasitol., 2006, 63, 125-183.
26. Barrett, M. P.; Fairlamb, A. H. The biochemical basis of arsenicaldiamidine cross-resistance in African trypanosomes. Parasitol. Today, 1999, 15, 136-140.
27. Tovar, J.; Cunningham, M. L.; Smith, A. C.; Croft, S. L.; Fairlamb, A. H. Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival. Proc. Natl. Acad. Sci. USA, 1998, 95, 5311-5316.
28. Russo, I.; Oksman, A.; Vaupel, B.; Goldberg, D. E. A calpain unique to alveolates is essential in Plasmodium falciparum and its knockdown reveals an involvement in pre-S-phase development. Proc. Natl. Acad. Sci. USA, 2009, 106, 1554-1559.
29. Armstrong, C. M.; Goldberg, D. E. An FKBP destabilization domain modulates protein levels in Plasmodium falciparum. Nat. Methods, 2007, 4, 1007-1009.
30. Herm-Götz, A.; Agop-Nersesian, C.; Münter, S.; Grimley, J. S.; Wandless, T. J.; Frischknecht, F.; Meissner, M. Rapid control of protein level in the apicomplexan Toxoplasma gondii. Nat. Methods, 2007, 4, 1003-1005.
31. da Silva, L. M.; Owens, K. L.; Murta, S. M. F.; Beverley, S. M. Regulated expression of the Leishmania major surface virulence factor lipophosphoglycan using conditionally destabilized fusion proteins. Proc. Natl. Acad. Sci. USA, 2009, 106, 7583-7588.
32. Carvalho, T. G.; Menard, R. Manipulating the Plasmodium genome. Curr. Issues Mol. Biol., 2005, 7, 39-55.
33. Beverley, S. M. Protozomics: Trypanosomatid parasite genetics comes of age. Nat. Rev. Genet., 2003, 4, 11-19.
34. Morris, J. C.; Morris, M. T.; Lee, S. Y.; Toole, W. P.; Seifert, C. M.; Acosta-Serrano, A. Reverse and forward genetics as practical approaches for post-genome studies. In Trypanosomes After the Genome, Barry, D., McCulloch, R., Mottram, J., Acosta-Serrano, A., Eds.; Horizon Bioscience: Wymondham, UK, 2007; pp 49-70.
35. Carvalho, T. G.; Ménard, R. Manipulating the Plasmodium genome. In: Malaria Parasites: Genomes and Molecular Biology, Waters, A. P., Janse, C. J., Eds.; Caister Academic Press: Wymondham, UK, 2004; pp. 101-134.
36. Soldati, D.; Meissner, M. Toxoplasma gondii a Model Organism for the Apicomplexans? In Malaria Parasites: Genomes and Molecular Biology, Waters, A. P., Janse, C. J., Eds.; Caister Academic Press: Wymondham, UK, 2004; pp 135-165.
37. Wang, C. C. Validating targets for antiparasite chemotherapy. Parasitology, 1997, 114, S31-S44.
38. Gutteridge, W. E. Designer drugs: pipe-dreams or realities? Parasitology, 1997, 114, S145-S151.
39. GueirosFilho, F. J.; Beverley, S. M. Selection against the dihydrofolate reductase-thymidylate synthase (DHFR-TS) locus as a probe of genetic alterations in Leishmania major. Mol. Cell. Biol., 1996, 16, 5655-5663.
40. Pedrosa, A. L.; Cruz, A. K. The effect of location and direction of an episomal gene on the restoration of a phenotype by functional complementation in Leishmania. Mol. Biochem. Parasitol., 2002, 122, 141-148.
41. Li, F.; Hua, S. B.; Wang, C. C.; Gottesdiener, K. M. Procyclic Trypanosoma brucei cell lines deficient in ornithine decarboxylase activity. Mol. Biochem. Parasitol., 1996, 78, 227-236.
42. Jiang, Y. Q.; Roberts, S. C.; Jardim, A.; Carter, N. S.; Shih, S.; Ariyanayagam, M.; Fairlamb, A. H.; Ullman, B. Ornithine decarboxylase gene deletion mutants of Leishmania donovani. J. Biol. Chem., 1999, 274, 3781-3788.
43. Cruz, A.; Coburn, C. M.; Beverley, S. M. Double targeted gene replacement for creating null mutants. Proc. Natl. Acad. Sci. USA, 1991, 88, 7170-7174.
44. Wyllie, S.; Oza, S. L.; Patterson, S.; Spinks, D.; Thompson, S.; Fairlamb, A. H. Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods. Mol. Microbiol., 2009, 74, 529-540.
45. Sienkiewicz, N.; Jaroslawski, S.; Wyllie, S.; Fairlamb, A. H. Chemical and genetic validation of dihydrofolate reductasethymidylate synthase as a drug target in African trypanosomes. Mol. Microbiol., 2008, 69, 520-533.
46. Li, F.; Hua, S. B.; Wang, C. C.; Gottesdiener, K. M. Trypanosoma brucei brucei: Characterization of an ODC null bloodstream form mutant and the action of m-difluoromethylornithine. Exp. Parasitol., 1998, 88, 255-257.
47. Cruz, A. K.; Titus, R.; Beverley, S. M. Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc. Natl. Acad. Sci. USA, 1993, 90, 1599-1603.
48. Howell, E. E.; Foster, P. G.; Foster, L. M. Construction of a dihydrofolate reductase-deficient mutant of Escherichia coli by gene replacement. J. Bacteriol., 1988, 170, 3040-3045.
49. Wirtz, E.; Leal, S.; Ochatt, C.; Cross, G. A. M. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol. Biochem. Parasitol., 1999, 99, 89-101.
50. Krieger, S.; Schwarz, W.; Ariyanayagam, M. R.; Fairlamb, A. H.; Krauth-Siegel, R. L.; Clayton, C. Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol., 2000, 35, 542-552.
51. Taylor, M. C.; Kelly, J. M. pTcINDEX: a stable tetracyclineregulated expression vector for Trypanosoma cruzi. BMC. Biotechnol., 2006, 6, 32.
52. Alibu, V. P.; Storm, L.; Haile, S.; Clayton, C.; Horn, D. A doubly inducible system for RNA interference and rapid RNAi plasmid construction in Trypanosoma brucei. Mol. Biochem. Parasitol., 2005, 139, 75-82.
53. Ullu, E.; Tschudi, C.; Chakraborty, T. RNA interference in protozoan parasites. Cell Microbiol., 2004, 6, 509-519.
54. Peacock, C. S.; Seeger, K.; Harris, D.; Murphy, L.; Ruiz, J. C.; Quail, M. A.; Peters, N.; Adlem, E.; Tivey, A.; Aslett, M.; Kerhornou, A.; Ivens, A.; Fraser, A.; Rajandream, M. A.; Carver, T.; Norbertczak, H.; Chillingworth, T.; Hance, Z.; Jagels, K.; Moule, S.; Ormond, D.; Rutter, S.; Squares, R.; Whitehead, S.; Rabbinowitsch, E.; Arrowsmith, C.; White, B.; Thurston, S.; Bringaud, F.; Baldauf, S. L.; Faulconbridge, A.; Jeffares, D.; Depledge, D. P.; Oyola, S. O.; Hilley, J. D.; Brito, L. O.; Tosi, L. R. O.; Barrell, B.; Cruz, A. K.; Mottram, J. C.; Smith, D. F.; Berriman, M. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet., 2007, 39, 839-847.
55. Taylor, M. C.; Kaur, H.; Blessington, B.; Kelly, J. M.; Wilkinson, S. R. Validation of spermidine synthase as a drug target in African trypanosomes. Biochem. J., 2008, 409, 563-569.
56. Torrie, L. S.; Wyllie, S.; Spinks, D.; Oza, S. L.; Thompson, S.; Harrison, J. R.; Gilbert, I. H.; Wyatt, P. G.; Fairlamb, A. H.; Frearson, J. A. Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis. J. Biol. Chem., 2009, 284, 36137-36145.
57. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug. Discov., 2004, 3, 711-715.
58. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23, 3-25.
59. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug. Discov. 2002, 1, 727-730.
60. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov., 2007, 6, 29-40.
61. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem., 2005, 48, 2518-2525.
62. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol., 2007, 25, 71-75.
63. Keller, T. H.; Pichota, A.; Yin, Z. A practical view of 'druggability'. Curr. Opin. Chem. Biol., 2006, 10, 357-361.
64. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem., 2003, 46, 1250-1256.
65. Vieth, M.; Siegel, M. G.; Higgs, R. E.; Watson, I. A.; Robertson, D. H.; Savin, K. A.; Durst, G. L.; Hipskind, P. A. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem., 2004, 47, 224-232.
66. Ritchie, T. J.; Luscombe, C. N.; Macdonald, S. J. F. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J. Chem. Inf. Model., 2009, 49, 1025-1032.
67. Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res., 1999, 16, 1514-1519.
68. Eastman, R. T.; Fidock, D. A. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev Microbiol., 2009, 7, 864-874.
69. Jennings, F. W. Future prospects for the chemotherapy of human trypanosomiasis 2. Combination chemotherapy and African trypanosomiasis. Trans. R. Soc. Trop. Med. Hyg., 1990, 84, 618-621.
70. Rivers, E. C.; Mancera, R. L. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today, 2008, 13, 1090-1098.
71. Kerb, R.; Fux, R.; Morike, K.; Kremsner, P. G.; Gil, J. P.; Gleiter, C. H.; Schwab, M. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect. Dis., 2009, 9, 760-774.